Gerard Sanacora
#132,613
Most Influential Person Now
American neuroscientist
Gerard Sanacora's AcademicInfluence.com Rankings
Gerard Sanacorabiology Degrees
Biology
#11328
World Rank
#14716
Historical Rank
Neuroscience
#1827
World Rank
#1883
Historical Rank
Download Badge
Biology
Why Is Gerard Sanacora Influential?
(Suggest an Edit or Addition)According to Wikipedia, Gerard Sanacora is an American translational neuroscientist. Upon earning his bachelor's degree from Stony Brook University in 1986, Sanacora entered the Medical Scientist Training Program, completing his doctorate and medical degree at Stony Brook in 1992 and 1994, respectively. He joined the Yale School of Medicine, where he was named George D. Gross and Esther S. Gross Professor of Psychiatry in 2018. Sanacora is a fellow of the American College of Neuropsychopharmacology.
Gerard Sanacora's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications (2008) (1112)
- The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission (2011) (1102)
- Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) (941)
- Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders (2012) (855)
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (2008) (812)
- Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. (2004) (749)
- Inhibition of hypothalamic neuropeptide Y gene expression by insulin. (1992) (573)
- Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy (1999) (551)
- Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments (2002) (517)
- Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography (1998) (512)
- Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. (2002) (448)
- Increased cortical GABA concentrations in depressed patients receiving ECT. (2003) (432)
- Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments (2019) (404)
- The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. (2017) (392)
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole (2010) (390)
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders (2017) (356)
- Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond (2013) (352)
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. (2016) (334)
- Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation. (1990) (334)
- Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. (2015) (297)
- A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression (2000) (286)
- Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial (2005) (279)
- Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. (1999) (275)
- Beyond Monoamines: Glutamatergic Function in Mood Disorders (2005) (270)
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (2018) (265)
- Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders (2017) (264)
- Overview of glutamatergic neurotransmission in the nervous system (2012) (250)
- Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses (2013) (229)
- Lower synaptic density is associated with depression severity and network alterations (2019) (218)
- Ketamine: A Paradigm Shift for Depression Research and Treatment (2019) (210)
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) (2018) (203)
- Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects (2013) (203)
- N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder (2005) (199)
- Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients (2012) (196)
- From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders (2013) (193)
- Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms (2007) (193)
- The NMDA receptor as a therapeutic target in major depressive disorder. (2007) (192)
- The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS (2011) (177)
- Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders (2003) (155)
- Riluzole in the Treatment of Mood and Anxiety Disorders (2008) (155)
- Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects (2016) (151)
- Reduced Density of Calbindin Immunoreactive GABAergic Neurons in the Occipital Cortex in Major Depression: Relevance to Neuroimaging Studies (2010) (140)
- KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS (2016) (140)
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. (2021) (137)
- GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. (2007) (135)
- The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? (2018) (135)
- Intravenous arketamine for treatment-resistant depression: open-label pilot study (2020) (135)
- Glutamate metabolism in major depressive disorder. (2014) (133)
- Antidepressant-Like Effects of Ceftriaxone in Male C57BL/6J Mice (2007) (132)
- Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. (2000) (132)
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. (2019) (128)
- The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects (2018) (116)
- Sex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy (2005) (116)
- Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). (2020) (112)
- 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism (2012) (111)
- Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting (2012) (107)
- Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder (2012) (105)
- Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression (2006) (105)
- Bi-Ancestral Depression GWAS in the Million Veteran Program and Meta-Analysis in >1.2 Million Subjects Highlights New Therapeutic Directions (2021) (99)
- A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (96)
- Cortical γ-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy (2006) (91)
- Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin (2020) (90)
- Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression (2017) (90)
- Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study (2016) (88)
- Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. (2006) (88)
- A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. (2019) (87)
- Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression (2006) (86)
- Antidepressant effect of ketamine during ECT. (2005) (85)
- Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). (2020) (84)
- Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? (2015) (82)
- Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression (2017) (81)
- Targeting glial physiology and glutamate cycling in the treatment of depression. (2009) (81)
- Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? (2015) (78)
- Cortical GABA levels in primary insomnia. (2012) (78)
- Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response (2004) (78)
- Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors (2004) (77)
- Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. (2009) (76)
- Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice (2012) (75)
- Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic (2017) (75)
- In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5 (2015) (74)
- Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression (2017) (73)
- Intravenous Ethanol Infusion Decreases Human Cortical γ-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla (2012) (72)
- Riluzole augmentation for treatment-resistant depression. (2004) (72)
- A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. (2017) (68)
- Genotype-controlled analysis of plasma dopamine β-hydroxylase activity in psychotic unipolar major depression (2002) (66)
- Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis. (2017) (66)
- ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment (2001) (64)
- Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT (2003) (60)
- Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder (2014) (58)
- Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. (2004) (57)
- Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. (2015) (56)
- Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. (2017) (53)
- Monoamine depletion in unmedicated depressed subjects (2002) (53)
- Computerized ambulatory monitoring in mood disorders: Feasibility, compliance, and reactivity (2010) (51)
- Major depression: emerging therapeutics. (2008) (47)
- Glutamate-based depression GBD. (2012) (46)
- Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus (2008) (41)
- Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. (2006) (40)
- Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. (2011) (40)
- Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2020) (38)
- Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. (2018) (38)
- The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development (2018) (37)
- The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders (2021) (36)
- Cortical Inhibition, Gamma-Aminobutyric Acid, and Major Depression: There Is Plenty of Smoke but Is There Fire? (2010) (36)
- Cell-type specific modulation of NMDA receptors triggers antidepressant actions (2020) (34)
- Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. (2019) (34)
- Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. (2018) (32)
- New understanding of mechanisms of action of bipolar medications. (2008) (32)
- Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity? (2014) (31)
- Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression (2018) (31)
- KETAMINE: A POTENTIAL RAPID‐ACTING ANTISUICIDAL AGENT? (2016) (31)
- A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder (2017) (30)
- ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. (2019) (28)
- Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the Antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial (2018) (27)
- Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. (2001) (25)
- Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders (2017) (25)
- Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. (2021) (25)
- Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder (2011) (25)
- The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms To the Editor: (2016) (22)
- Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders (2017) (22)
- Developmental Aspect of Differences in Hypothalamic Preproneuropeptide Y Messenger Ribonucleic Acid Content in Lean and Genetically Obese Zucker Rats (1992) (22)
- Regulation of Extrasynaptic Glutamate Levels as a Pathophysiological Mechanism in Disorders of Motivation and Addiction (2015) (22)
- Brain–phenotype models fail for individuals who defy sample stereotypes (2022) (21)
- Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine. (2019) (20)
- Mutation screen of the glutamate decarboxylase‐67 gene and haplotype association to unipolar depression (2004) (20)
- Can Cognitive Behavioral Therapy Reduce Relapse Rates of Depression After ECT? A Preliminary Study (2006) (18)
- Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. (2020) (18)
- GWAS of Depression Phenotypes in the Million Veteran Program and Meta-analysis in More than 1.2 Million Participants Yields 178 Independent Risk Loci (2020) (17)
- Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor. (2018) (16)
- Macro- and Microscale Stress–Associated Alterations in Brain Structure: Translational Link With Depression (2021) (16)
- Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial (2021) (15)
- Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study (2019) (15)
- The roles of glutamate receptors across major neurological and psychiatric disorders. (2012) (15)
- Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. (2009) (14)
- Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) (2018) (14)
- Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. (2009) (14)
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (2019) (14)
- S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression (2018) (13)
- S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole (2010) (13)
- Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder (2020) (13)
- 304. Cortical GABA reduced in unipolar but not bipolar depression (2000) (12)
- Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression (2019) (12)
- Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (2019) (12)
- Visual hallucinations from the addition of riluzole to memantine and bupropion. (2006) (11)
- What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder. (2016) (10)
- Reduced Cortical g -Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy (1999) (10)
- Binding to Metabotropic Glutamate Receptor Subtype 5 (2014) (10)
- Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality (2021) (10)
- mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. (2022) (10)
- Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy (2017) (9)
- The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study (2021) (9)
- Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. (2021) (9)
- It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
- Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) (9)
- Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders (2014) (8)
- A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. (2015) (8)
- Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk (2021) (7)
- Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression? (2020) (7)
- Early life stress and glutamate neurotransmission in major depressive disorder (2020) (6)
- Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. (2022) (6)
- Scopolamine rapidly increases mTORC1 signaling, synaptogenesis, and antidepressant behavioral responses (2013) (6)
- Hypothalamic Neuropeptide Y Expression in Normal and Aberrant Metabolic Homeostasis (1990) (5)
- Riluzole augmentation in treatment-refractory obsessive- compulsive disorder: a pilot placebo-controlled trial (2015) (5)
- Applications of Magnetic Resonance Spectroscopy to Psychiatry (1999) (5)
- Reviewing medications for bipolar disorder: understanding the mechanisms of action. (2009) (5)
- F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET (2018) (5)
- Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review (2022) (5)
- Ketamine: A Review for Clinicians. (2018) (5)
- Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice (2011) (5)
- Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. (2013) (4)
- 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS (1999) (4)
- Gene expression of peptidergic signals: Effects of steroids (1992) (4)
- The need for outcome studies. (1996) (4)
- Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models (2020) (3)
- Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. (2022) (3)
- Depressed diabetics : A neuroimmunologic syndrome? (2005) (3)
- Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders (2003) (3)
- Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants (2012) (2)
- Reply to: Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion (2017) (2)
- S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital (2018) (2)
- Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial (2022) (2)
- 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations (2019) (2)
- Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research (2016) (2)
- Stress, Anxiety, and Depression and the Role of Glutamate Neurotransmission (2015) (2)
- 157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department (2010) (2)
- A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Non-Suicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. (2022) (2)
- Intravenous ethanol infusion decreases human cortical GABA and NAA as measured with 1H-MRS at 4T (2012) (1)
- POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (2019) (1)
- Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. (2022) (1)
- Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. (2023) (1)
- The Revolution in Rapid-Acting Antidepressants (2013) (1)
- Ketamine-induced changes in [11C]ABP688 binding in healthy human subjects (2013) (1)
- Guest Editorial (2012) (1)
- Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans (2022) (1)
- Authorship Credit for Large Clinical Trials. (2018) (1)
- Ketamine for the Treatment of Depression-Reply. (2017) (1)
- At-home ketamine; still a lot to learn. (2022) (1)
- P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study (2014) (1)
- Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies (2016) (1)
- A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized 1H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator. (2020) (1)
- 201. Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression (2017) (1)
- 322. Transcranial magnetic stimulation in treatment-refractory depression (1998) (1)
- Treatment Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Without Evidence of Early Response: A Pooled Post Hoc Analysis of ASPIRE. (2022) (1)
- 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects (2000) (0)
- 24. Quantification of cortical GABA levels in neuropsychiatric patients (1998) (0)
- Exploring New Therapeutic Areas in the Treatment of Depression and Bipolar Disorder (2013) (0)
- S.20.02 Targeting glutamatergic transmission in the development of novel therapeutics for mood and anxiety disorders (2013) (0)
- The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives (2019) (0)
- Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine’s Rapid Onset Antidepressant Actions in Rodent Models (2018) (0)
- 1002. Ketamine as a Treatment for Adolescent Major Depressive Disorder (2017) (0)
- S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis (2019) (0)
- 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients (2019) (0)
- 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting (1999) (0)
- Changes Following Electroconvulsive Therapy : A Systematic Review and Meta-analysis (2018) (0)
- P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial (2009) (0)
- 662. Ketamine and Rapastinel Effects on Glutamate Cycling (2017) (0)
- New Medication Strategies for Non-responsive Depressed Patients (2012) (0)
- Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide : Results of a Double-Blind , Randomized , Placebo-Controlled Study (2018) (0)
- Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2021) (0)
- 305. Reduced cortical GABA in depression is not due to decreased gray matter (2000) (0)
- Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies (2014) (0)
- Reduced Energy Per Cycle, a Marker of Glutamatergic Synaptic Strength, in Individuals Diagnosed with PTSD and Depression (2021) (0)
- The role of the glutamatergic system in the pathophysiology and treatment of mood disorders (2006) (0)
- Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder (2022) (0)
- Neurobiology and Treatment of Depression (2007) (0)
- Ketamine and Glutamatergic Compounds: Exploring Biomarkers and Mechanisms Related to Rapid Antidepressant Action (2017) (0)
- Rapid-Acting Antidepressants: Where Do We Stand with Ketamine? (2014) (0)
- Co-occurring Catatonia and Posterior Reversible Encephalopathy Syndrome Responsive to Electroconvulsive Therapy. (2017) (0)
- The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders (2021) (0)
- The Search for Antidepressants - An Integrative View of Drug Discovery (2017) (0)
- Imaging the Effect of Ketamine on Synaptic (SV2A) Density (2021) (0)
- Shedding Light on Glutamate for Mood Disorders (2012) (0)
- A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (0)
- Lower synaptic density is associated with depression severity and network alterations (2019) (0)
This paper list is powered by the following services:
Other Resources About Gerard Sanacora
What Schools Are Affiliated With Gerard Sanacora?
Gerard Sanacora is affiliated with the following schools:
